SciGen Announces Distribution Agreement with Medic Plus Pharmaceuticals (Pty) Ltd to Extend Presence in Southern African Markets

July 11, 2023, Singapore – SciGen Pte Ltd (“SciGen”), a rapidly growing biopharmaceutical company, is pleased to announce the signing of a distribution agreement with Medic Plus Pharmaceuticals (Pty) Ltd (“Medic Plus”), one of Botswana’s fastest growing companies in the wholesale and distribution business of Pharmaceutical Products and Allied Substances. This strategic partnership aims to expand SciGen’s presence in the markets of Botswana, Namibia, Lesotho, and Zambia in the Southern African Region.

With Gensulin®, a high-quality European recombinant human insulin product, SciGen aims to revolutionize diabetes management in Southern Africa. The manufacturing facilities, stringent quality control measures, and commitment to patient-centric healthcare have contributed to Gensulin®’s recognition as an effective, safe, and stable product with 20 years of experience.

The partnership with Medic Plus will leverage their deep understanding of the Southern African market and extensive distribution network, enabling us to effectively reach patients in Botswana, Namibia, Lesotho, and Zambia. By combining our expertise and resources, we aim to ensure that Gensulin® is readily available to those in need, thereby improving access to quality diabetic care in the region.

SciGen’s dedication to promoting innovative healthcare solutions and improving patient lives aligns with Medic Plus Pharmaceuticals’ commitment to quality and excellence. This alliance represents a milestone for both companies and their shared vision of making a positive impact on healthcare in Southern Africa.

As part of this agreement, SciGen will commence the registration process in the aforementioned markets in the third quarter of 2023. The launch of Gensulin® is anticipated to take place in the first quarter of 2025, pending the successful completion of the registration process and regulatory approvals.

SciGen’s primary objective is to meet the growing need for cost-effective healthcare solutions in Africa, and the strategy of a range of Gensulin® and other products will be fulfilling this demand. This strategy offers a significant cost advantage over the branded counterparts without compromising efficacy or safety, making them an attractive option for patients. To ensure widespread availability and accessibility, the plan is to register Gensulin® in a maximum number of markets especially focusing on countries from South, East, and West African regions. It will pave the way for establishing long-term substantial partnerships and distribution networks with local healthcare providers, ensuring needy patients are supplied with high-quality and affordable products. Going forward will be adding more products to explore potential ways SciGen can collaborate to improve healthcare access in Africa.

About SciGen Pte Ltd

SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and are present commercially in all 6 continents. With exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families. To learn more about SciGen, visit:

About Medic Plus Pharmaceuticals (Pty) Ltd

Medic Plus is one of Botswana’s fastest-growing companies in the wholesale and distribution business of Pharmaceutical Products and Allied Substances. Focus on excellent customer care support by continuously setting bench-marking standards in the industry. Established in 2019 and registered with the Botswana Medicines Regulatory Authority, we focus on excellent customer care support by continuously setting bench-marking standards in the industry. We emphasize the effective, efficient, and safe handling, storage, and distribution of such products ensuring their identity and quality during all aspects of the wholesaling and distribution process. We deliver to all corners of Botswana and beyond with utmost efficiency while upholding the highest medicine handling standards. For more information, please visit:

Leave a Reply

Your email address will not be published. Required fields are marked *